<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003017</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065597</org_study_id>
    <secondary_id>ECOG-E1E96</secondary_id>
    <nct_id>NCT00003017</nct_id>
  </id_info>
  <brief_title>Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix</brief_title>
  <official_title>Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by&#xD;
      stimulating a person's white blood cells to kill cancer cells in the cervix.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of interleukin-12 in treating patients who&#xD;
      have advanced or recurrent cancer of the cervix.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rates, duration of response, and survival in women with&#xD;
      advanced, recurrent, or inoperable cervical cancer treated with interleukin-12. II. Determine&#xD;
      the toxic effects of systemic interleukin-12 in these patients. III. Correlate response to&#xD;
      therapy and survival with the presence or absence of human papilloma virus (HPV), and the&#xD;
      specific subtype of HPV, in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to prior chemotherapy (yes vs no). Patients&#xD;
      receive induction interleukin-12 IV over 5-20 seconds on day -13 and then daily on days 1-5.&#xD;
      Treatment continues every 21 days in the absence of unacceptable toxicity or disease&#xD;
      progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 78 patients (39 per stratum) will be accrued for this study&#xD;
      within 26 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage IV or recurrent squamous cell,&#xD;
        adenosquamous, or adenocarcinoma of the uterine cervix including: Lung, liver, lymph node,&#xD;
        or skin metastases OR Retroperitoneal disease OR Other advanced measurable disease OR&#xD;
        Positive paraaortic lymph nodes Measurable disease that is beyond the scope of conventional&#xD;
        radiation therapy or surgery, or recurrent after radiation therapy or surgery Measurable,&#xD;
        recurrent disease within a previously irradiated field must have increased in size by 100%&#xD;
        on at least 2 successive scans, MRI, or physical examinations&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not&#xD;
        specified Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times&#xD;
        the upper limit of normal (ULN) AST and ALT no greater than 2 times ULN Renal: Creatinine&#xD;
        no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: No New&#xD;
        York Heart Association class III/IV heart disease No uncontrolled congestive heart failure&#xD;
        or angina Pulmonary: No chronic obstructive pulmonary disease Gastrointestinal: No evidence&#xD;
        of active gastrointestinal bleeding No active peptic ulcer disease No inflammatory bowel&#xD;
        disease Other: Normal diet required No known active infections HIV negative AIDS-related&#xD;
        complex (ARC) negative No substance abuse or psychiatric problems No evidence of autoimmune&#xD;
        disease No other prior invasive malignancy except resected basal cell or squamous cell skin&#xD;
        cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: 1 prior biologic therapy allowed At least 4&#xD;
        weeks since prior biologic therapy Chemotherapy: 1 prior adjuvant chemotherapy regimen&#xD;
        allowed 1 prior chemotherapy regimen for advanced disease allowed At least 4 weeks since&#xD;
        prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent steroid&#xD;
        therapy No concurrent megestrol acetate Radiotherapy: See Disease Characteristics No&#xD;
        concurrent radiotherapy Surgery: See Disease Characteristics At least 2 weeks since prior&#xD;
        surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Wadler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunterdon Regional Cancer Center</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS; Eastern Cooperative Oncology Group. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 2004 Mar;92(3):957-64. doi: 10.1016/j.ygyno.2003.12.022.</citation>
    <PMID>14984966</PMID>
  </results_reference>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

